|
Active substance |
ruxolitinib |
|
Holder |
Novartis Pharma |
|
Status |
Running |
|
Indication |
Treatment of Corticoid-refractory acute graft vs. host disease after allogeneic stem cell transplantation in pediatric patients <12 years old, who cannot be adequately treated with commercially available alternatives. |
|
Public documents |
|
|
Last update |
01/06/2023 |
Jakavi
Last updated on